Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 3/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905603 | 1.00 | GAA (0.54) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5316912 | 1.00 | GAA (0.54) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL63670 | 0.85 | KMT2A (0.64) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4429295 | 0.83 | MAPT (0.54) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3094416 | 0.82 | GAA (0.45) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL3094410 | 0.82 | GAA (0.45) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL3190543 | 0.82 | GAA (0.45) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL82476 | 0.81 | KMT2A (0.51) | GAAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16373718 | 0.80 | GAA (0.59) | GAAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL1190859 | 0.79 | OXTR (0.51) | GAAMAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | US | claimed |
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | US | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | MAP4K2, MAP3K6, MAP3K2 | GAA 2160/4885MAPT 2641/4885KMT2A 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.